Novavax, Inc. (BMV:NVAX)
Mexico flag Mexico · Delayed Price · Currency is MXN
110.00
-9.00 (-7.56%)
Last updated: Apr 3, 2025

Novavax Company Description

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally.

The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.

It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax, Inc.
Country United States
Founded 1987
Industry Biological Products, Except Diagnostic Substances
Employees 952
CEO John Jacobs

Contact Details

Address:
700 Quince Orchard Road
Gaithersburg, Delaware 20878
United States
Phone 240 268 2000
Website global.novavax.com

Stock Details

Ticker Symbol NVAX
Exchange Mexican Stock Exchange
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
SIC Code 2836

Key Executives

Name Position
John Jacobs Chief Executive Officer
James Kelly Chief Financial Officer